Search Results

Your search for Leisha A. Emens, MD, PhD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / ESMO 2019 Congress

Sherene Loi, MD, PhD, and Leisha A. Emens, MD, PhD, on HER2-Positive Breast Cancer: KATE2 Study of Atezolizumab/Trastuzumab Emtansine

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre at the University of Melbourne, and Leisha A. Emens, MD, PhD, of UPMC Hillman Cancer Center, discuss overall survival in this phase II study of atezolizumab/trastuzumab emtansine (T-DM1) vs placebo/T-DM1 in previously treated HER2-positive...

breast cancer

immunotherapy

By Matthew Stenger / Thursday, October 4, 2018 5:38 PM

Long-Term Outcomes With Anti–PD-L1 Treatment in Metastatic Triple-Negative Breast Cancer

In a long-term follow-up of a phase I trial reported in JAMA Oncology, Emens et al found that single-agent atezolizumab (Tecentriq) produced enduring benefit in patients with metastatic triple-negative breast cancer after stable or responding disease and in first-line treatment. Study Details In...

Apr

Today In Oncology

Search Results

Your search for Leisha A. Emens, MD, PhD matches 2 pages

Sherene Loi, MD, PhD, and Leisha A. Emens, MD, PhD, on HER2-Positive Breast Cancer: KATE2 Study of Atezolizumab/Trastuzumab Emtansine

Long-Term Outcomes With Anti–PD-L1 Treatment in Metastatic Triple-Negative Breast Cancer

Insights From the 2023 International Society of Geriatric Oncology Conference

Illuminating a Potential Culprit in Melanoma Treatment Resistance

Oxaliplatin-Based Adjuvant Therapy in Older Patients with Stage III Colon Cancer

Newly Diagnosed Locally Advanced HNSCC Adding Pembrolizumab to Concurrent Chemoradiotherapy

Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone